Tags : advanced RCC

Biotech

Exelixis’ Cabometyx (cabozantinib) Recommended by the NCCN in its Clinical

Shots: Guidelines for Kidney Cancer: CABOMETYX (TKi) is recommended for 1L RCC patients in the poor- and intermediate-risk groups (Category 2A), 1L treatment for favourable-risk patients (Category 2B), and for previously treated patients (Category 1) The (Category 2A) guidelines are based on P-II CABOSUN trial (N=157) in (ratio 1:1) administering cabozantinib (60mg qw)/sunitinib (50mg qw,4 […]Read More